1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence
LK Carr, D Steele, S Steele, D Wagner… - International …, 2008 - Springer
LK Carr, D Steele, S Steele, D Wagner, R Pruchnic, R Jankowski, J Erickson, J Huard…
International Urogynecology Journal, 2008•SpringerWe hereby report a 1-year follow-up on eight women in the first North America trial in which
stress urinary incontinence (SUI) was treated with muscle-derived stem cell injections. Mean
and median follow-up in this group was 16.5 and 17 months (range 3–24 months).
Improvement in SUI was seen in five of eight women, with one achieving total continence.
Onset of improvement was between 3 and 8 months after injection. Cure or improvement
continued at a median of 10 months. No serious adverse events were reported.
stress urinary incontinence (SUI) was treated with muscle-derived stem cell injections. Mean
and median follow-up in this group was 16.5 and 17 months (range 3–24 months).
Improvement in SUI was seen in five of eight women, with one achieving total continence.
Onset of improvement was between 3 and 8 months after injection. Cure or improvement
continued at a median of 10 months. No serious adverse events were reported.
Abstract
We hereby report a 1-year follow-up on eight women in the first North America trial in which stress urinary incontinence (SUI) was treated with muscle-derived stem cell injections. Mean and median follow-up in this group was 16.5 and 17 months (range 3–24 months). Improvement in SUI was seen in five of eight women, with one achieving total continence. Onset of improvement was between 3 and 8 months after injection. Cure or improvement continued at a median of 10 months. No serious adverse events were reported.
Springer